Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on August 13, 2025
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
GlobeNewswire
·
August 13, 2025
- Continues recruitment and opens US and EU sites for the Phase 2B/3 MIRACLE trial - 20+ additional clinical sites in Europe and the US expected to begin recruitment by the end of Q3 - Anticipated data readout of MIRACLE Part A targeted before end of 2025 …
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
GlobeNewswire
·
August 13, 2025
COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through …
Smart Medical Devices Market to Grow at 17.1% CAGR Through 2030
GlobeNewswire
·
August 13, 2025
Boston, Aug. 13, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Smart Medical Devices: Global Markets” is projected to grow from $87.7 billion in 2025 to $193.3 billion by the end of 2030, at a compound annual growth rate (CAGR) …
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
GlobeNewswire
·
August 13, 2025
BERKELEY, Calif. and MAINZ, Germany, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert …
Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership
GlobeNewswire
·
August 13, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …
Clinical Microbiology Market to Reach $6.9 Billion by 2029, Driven by Advanced Diagnostics and Regulatory Demand | MarketsandMarkets™.
GlobeNewswire
·
August 13, 2025
Delray Beach, FL, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Stringent quality standards, technological innovation, and global healthcare expansion accelerate market growth The global clinical microbiology market, valued at US$4.8 billion in 2023, stood at US$5.0 …
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
GlobeNewswire
·
August 13, 2025
SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in …
Clene to Present at the Emerging Growth Conference
GlobeNewswire
·
August 13, 2025
SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment …
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 13, 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial …
First LockeT Cases Completed in Germany
GlobeNewswire
·
August 13, 2025
FORT MILL, S.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that the first …
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
GlobeNewswire
·
August 13, 2025
First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel …
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
SOLANA BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, …
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 13, 2025
Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for future ganaxolone royalties, delivering capital to the …
BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology
GlobeNewswire
·
August 13, 2025
SUNNYVALE, Calif. and UTRECHT, Netherlands, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CART-Tech, B.V., a …
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
GlobeNewswire
·
August 13, 2025
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company’s goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all …
ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025
GlobeNewswire
·
August 13, 2025
ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment …
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
GlobeNewswire
·
August 13, 2025
ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapies Med (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’s rapid dendritic cell activation in …
FOXO TECHNOLOGIES INC. ANNOUNCES THAT ITS COMMON STOCK CAN BE QUOTED AND TRADED ON THE OVER THE COUNTER MARKET FROM AUGUST 13, 2025.
GlobeNewswire
·
August 13, 2025
WEST PALM BEACH, FLORIDA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (“FOXO” or the “Company”) announces that it has received a letter from NYSE on August 12, 2025 confirming that NYSE Regulation has determined to commence proceedings to …
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
GlobeNewswire
·
August 13, 2025
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies …
ElevateBio BaseCamp Achieves ICMC™ Certification for Commercial Cell and Gene Therapy Manufacturing Capabilities
GlobeNewswire
·
August 13, 2025
ICMC certification delivered by Dark Horse Consulting certifies ElevateBio’s compliant and scalable manufacturing capabilities for advanced therapies using U.S. and E.U. commercial-level evaluation standards BaseCamp is the first genetic medicine …